Ralph Delnegro, DO
Ophthalmology · Neptune, NJNPI 1033297155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Sight Sciences, Inc. at 39.4% of the total.
Across 110 payments — averaging $32.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$1K
- Alcon$429
- Johnson & Johnson Surgical Vision, Inc.$425
- Rxsight Inc$187
- Oyster Point Pharma, Inc.$172
- AbbVie$139
- plus $794 from 19 others
Across 3 payments — averaging $19,800 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$59K
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$3,51799%
- Other$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 16 | $1,397 |
| Alcon | 25 | $429 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $425 |
| Rxsight Inc | 4 | $187 |
| Oyster Point Pharma, Inc. | 11 | $172 |
| AbbVie(2 entities) | 10 | $139 |
| Aerie Pharmaceuticals, Inc. | 2 | $138 |
| Dutch Ophthalmic, USA | 1 | $91 |
| Bausch & Lomb Americas Inc. | 5 | $81 |
| Kala Pharmaceuticals, Inc. | 5 | $76 |
| Novartis | 4 | $52 |
| Biotissue Holdings Inc. | 3 | $46 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $41 |
| Lensar, Inc. | 2 | $33 |
| Glaukos Corporation | 1 | $32 |
| Eyepoint US, Inc. | 2 | $31 |
| Sun Pharmaceutical Industries Inc. | 2 | $31 |
| Thea Pharma Inc. | 2 | $29 |
| Dompe US, Inc. | 1 | $18 |
| Omeros Corporation | 1 | $17 |
| Harrow Eye, LLC | 1 | $17 |
| NEW World Medical,inc. | 1 | $16 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Iridex Corporation | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,543 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 167 | $84,974 |
| RestasisCyclosporine | 68 | $58,457 |
| TyrvayaVarenicline Tartrate | 28 | $25,062 |
| Prednisolone Acetate | 754 | $23,438 |
| RocklatanNetarsudil Mesylat/Latanoprost | 47 | $21,368 |
| RhopressaNetarsudil Mesylate | 55 | $21,209 |
| XiidraLifitegrast | 25 | $19,982 |
| Cyclosporine | 24 | $17,512 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $17,463 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 90 | $15,359 |
| VyzultaLatanoprostene Bunod | 36 | $14,550 |
| Travoprost | 55 | $9,397 |
| Timolol Maleate | 260 | $9,126 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $8,965 |
| Brimonidine Tartrate | 373 | $8,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $139 | $160,894276 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $138 | $42,577102 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $81 | $34,53261 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $172 | $25,06228 claims |
| AlconSimbrinza | $429 | $8,96530 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $41 | $2,78214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Neptune
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.